| Literature DB >> 30025532 |
Yujie Yuan1,2, Jinning Ye1,2, Yufeng Ren3, Weigang Dai1,2, Jianjun Peng1,2, Shirong Cai1,2, Chuangqi Chen1,2, Min Tan1,2, Wu Song4,5, Yulong He6,7.
Abstract
BACKGROUND: The multidisciplinary team (MDT) discussion has earned increasing popularity for the delivery of cancer care. However, MDT meeting (MDTM) is time and resource intensive, and some efforts to optimize discussion processes are required. This study aims to investigate the efficiency of electronic list-based MDTM in treatment of gastrointestinal (GI) malignancy.Entities:
Keywords: Efficiency; Electronic checklist; Gastrointestinal malignancy; Multidisciplinary
Mesh:
Year: 2018 PMID: 30025532 PMCID: PMC6053746 DOI: 10.1186/s12957-018-1443-1
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Fig. 1Flow chart of this study. In the study period of 2015, patients received a traditional MDT meeting for clinical assessment and treatment; while in 2016, patients received our novel electronic checklist during the MDTM for clinical management
Fig. 2Comparisons of procedures between eMDT and cMDT meetings in management of gastrointestinal malignancy. A spreadsheet produced by EXCEL was employed for quick case review and MDT discussion in the eMDT group. PACS, picture archiving and communication systems; LIS, laboratory information system; HIS, hospital information system; AI, artificial intelligence (computing based on pre-defined program/rule)
Demographic and clinical characteristics of included patients during MDT discussion
| eMDT group ( | cMDT group ( | ||
|---|---|---|---|
| Including period | 01/01/16–31/12/16 | 01/01/15–31/12/15 | |
| Age, years | 55.4 ± 16.5 | 55.7 ± 16.5 | 0.529 |
| Gender, male to female | 1617:539 | 1138:380 | 0.844 |
| BMI, kg/m2 | 20.3 ± 6.1 | 20.8 ± 6.5 | |
| Comorbidity, | 0.695 | ||
| HTN | 465(21.6) | 310 (20.4) | |
| DM | 289 (13.4) | 193 (12.7) | |
| Othersa | 86 (4.0) | 59 (3.9) | |
| Cancer type, | 0.218 | ||
| Esophageal cancer | 159 (7.4) | 102 (6.7) | |
| Gastric cancer | 640 (29.7) | 419 (27.6) | |
| Colorectal cancer | 1030 (47.8) | 756 (49.8) | |
| GIST | 79 (3.7) | 73 (4.8) | |
| Othersb | 332 (15.4) | 209 (13.8) | |
| Meeting times, | 45 | 46 | NA |
| Cases, | 172.3 ± 31.5 | 126.6 ± 42.7 | 0.004 |
| Treatment plan, | 0.737 | ||
| Neoadjuvant therapy + surgery | 305 (14.1) | 205 (13.5) | |
| Surgery | 1583 (73.4) | 1131 (74.5) | |
| Palliative care | 270 (12.5) | 182 (12.0) | |
| cTNM stage, | 0.018 | ||
| I/II | 1190 (55.2) | 898 (59.2) | |
| III/IV | 966 (44.8) | 620 (40.8) | |
| pTNM stage, | 0.098 | ||
| I/II | 1226 (56.8) | 821 (54.1) | |
| III/IV | 930 (43.2) | 697 (45.9) |
P value < 0.05 indicates significant difference
eMDT electronic list-based MDT group, cMDT conventional MDT group, BMI body mass index, HTN hypertension, DM diabetes mellitus, GIST gastrointestinal stromal tumor, NA data not available
aOther diseases include chronic obstructive pulmonary disease, atherosclerosis, and chronic liver or renal disease
bOther cancers, such as pancreatic carcinoma, hepatic cancer, abdominal adenocarcinoma and peritoneal mesothelioma, were reviewed at the MDT meeting. Data are expressed as number (%) or as means ± SD, where appropriate
Efficiency analysis of MDT working through two different techniques
| eMDT group ( | cMDT group ( | ||
|---|---|---|---|
| Including Period | 01/01/16–31/12/16 | 01/01/15–31/12/15 | |
| Case complexity, | 0.070 | ||
| general | 1356 (62.9) | 933 (61.5) | |
| moderate | 598 (27.7) | 407 (26.8) | |
| complicate | 202 (9.4) | 178 (11.7) | |
| Cases per month, | 172.3 ± 31.5 | 126.6 ± 42.7 | 0.004 |
| Cases per meeting, | 47.9 ± 21.1 | 33.0 ± 9.5 | < 0.001 |
| Time cost per meeting, min | 149.4 ± 15.1 | 205.1 ± 32.7 | < 0.001 |
| Time cost per case, min | 3.1 ± 3.3 | 6.2 ± 4.9 | < 0.001 |
| Case type | |||
| general | 2.6 ± 1.6 | 4.5 ± 3.7 | < 0.001 |
| moderate | 3.8 ± 2.2 | 5.9 ± 3.1 | < 0.001 |
| complicate | 6.6 ± 3.8 | 7.2 ± 3.7 | 0.121 |
| Cancer type | |||
| Esophageal | 3.7 ± 2.9 | 4.2 ± 4.0 | 0.244 |
| Gastric | 3.6 ± 3.1 | 6.6 ± 4.2 | < 0.001 |
| Colorectal | 3.0 ± 2.2 | 6.2 ± 4.7 | < 0.001 |
| Others | 3.1 ± 2.7 | 5.8 ± 3.9 | < 0.001 |
P value < 0.05 indicates significant difference
Data present as means ± SD if no otherwise indicated
eMDT electronic list-based MDT group, cMDT conventional MDT group
Fig. 3Frequency and time cost comparisons in each month between two groups. a The percentage of discussed cases in each sequential month was compared between eMDT and cMDT groups, with subgroups of gastroesophageal and colorectal cancers compared meanwhile. b The average time cost in each sequential month was compared between eMDT and cMDT groups
Short-term outcomes of all patients following various multidisciplinary approaches
| eMDT group ( | cMDT group ( | ||
|---|---|---|---|
| Including Period | 01/01/16–31/12/16 | 01/01/15–31/12/15 | |
| Accuracy in tumor staginga, ratio(%) | 0.070 | ||
| Stage I | 326/372 (87.6) | 231/266 (86.8) | 0.810 |
| Stage II | 699/854 (81.8) | 386/555 (69.5) | < 0.001 |
| Stage III | 472/620 (76.1) | 289/450 (64.2) | < 0.001 |
| Stage IV | 292/310 (94.2) | 231/247 (93.5) | 0.859 |
| Overall LOS, days | 12.0 ± 7.5 | 15.1 ± 10.4 | < 0.001 |
| Esophageal cancer | 15.5 ± 6.8 | 18.7 ± 9.4 | < 0.001 |
| Gastric cancer | 16.1 ± 8.4 | 20.3 ± 10.3 | < 0.001 |
| Colorectal cancer | 10.4 ± 3.1 | 13.8 ± 8.3 | < 0.001 |
| Other malignancies | 7.3 ± 10.2 | 8.6 ± 11.8 | 0.161 |
| Overall LOPS, daysb | 8.1 ± 7.2 | 10.8 ± 8.7 | < 0.001 |
| Esophageal cancer | 10.2 ± 6.9 | 12.9 ± 7.2 | 0.003 |
| Gastric cancer | 11.5 ± 5.2 | 13.8 ± 6.9 | < 0.001 |
| Colorectal cancer | 6.3 ± 4.1 | 9.8 ± 5.7 | < 0.001 |
| Other malignancies | 6.1 ± 9.2 | 7.8 ± 9.3 | 0.031 |
| Complications, | 383 (17.6) | 293 (19.3) | 0.243 |
| Bowel obstruction | 206 (9.6) | 147 (9.7) | 0.910 |
| SSI | 125 (5.8) | 90 (5.9) | 0.887 |
| IAH | 28 (1.3) | 26 (1.7) | 0.331 |
| Othersc | 43 (2.0) | 31 (2.0) | 0.906 |
| Unplanned reoperation, | 21 (1.0) | 16 (1.0) | 0.867 |
LOS length of stay, LOPS length of postoperative stay, SSI surgical site infection, IAH intra-abdominal hemorrhage
aPercentage of correct stage in clinical staging as the pathological stage
bPatients receiving definitive operation were included for group comparison, with 1888 and 1336 cases in eMDT and cMDT groups respectively
cOther complications include fever, pulmonary infection, deep vein thrombosis, urinary tract infection and so on. Data are expressed as number (%) or means ± SD, where appropriate